Tech Company Financing Transactions

Tubulis Funding Round

EQT Life Sciences, Nextech Invest and Andera Partners participated in a $139.5 million Series B funding round for Tubulis. This venture round closed on 3/14/2024.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Life Sciences

Mailing Address

Butenandtstraße 1
Munich, 81377
Germany

Phone

Undisclosed

Website

www.tubulis.com

Email Address

[email protected]

Overview

Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Dominik Schumacher

        

Chief Marketing Officer

Günter Fingerle-Rowson

        

Chief Scientific Officer

Jonas Helma-Smets

        

Vice President

Olivier Marcq

        

VP - Bus. Development

Ingo Lehrke

        

VP - Regulatory Affairs

Armin Weidmann

        

Browse more venture capital transactions:

Prev: 3/14/2024: NeoTaste venture capital transaction
Next: 3/14/2024: Pi Health venture capital transaction

Share this article

News on VC Transactions

We report on funding rounds that are announced publicly. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary